Information Provided By: 
Fly News Breaks for March 20, 2015
KERX
Mar 20, 2015 | 07:55 EDT
After surveying 50 nephrologists/nurses/dietitians at U.S. dialysis clinics, Oppenheimer reported that dialysis providers it surveyed expect to prescribe Keryx's Auryxia in 11% of new starts and about 12% of switchers . As a result of this data points and other data from the survey, the firm expects Auryxia prescription trends to improve. It keeps an $18 price target and Outperform rating on the shares.
News For KERX From the Last 2 Days
There are no results for your query KERX
